Loading…
Morningstar Minerals LLC received an FDA Warning Letter on June 1, 2020, regarding drug products. Based on the limited metadata available, the specific violations and regulatory concerns cannot be fully detailed, as the warning letter subject line and issuing office information are not provided. This enforcement action indicates the FDA identified compliance issues with the company's drug manufacturing, marketing, or product claims, though the precise nature of these violations would require review of the complete letter. The case falls under FDA's drug product regulatory authority.